Arbutus reports strong financial results

Arbutus has announced its fourth quarter and full-year financial results for 2025, highlighting a robust financial position. The company reported cash, cash equivalents, and marketable securities totaling $91.5 million as of December 2025. A significant corporate update includes a $2.25 billion global settlement with Moderna. These results indicate a stable financial standing and a notable achievement through the settlement, positioning Arbutus favorably for future operations and strategic initiatives.